241 related articles for article (PubMed ID: 23836409)
1. Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Quik M; Mallela A; Ly J; Zhang D
Mov Disord; 2013 Sep; 28(10):1398-406. PubMed ID: 23836409
[TBL] [Abstract][Full Text] [Related]
2. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Bordia T; McGregor M; McIntosh JM; Decker MW; Quik M
Mov Disord; 2014 Apr; 29(4):508-17. PubMed ID: 24515328
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Mallela A; Sohn D; Carroll FI; Bencherif M; Letchworth S; Quik M
J Pharmacol Exp Ther; 2013 Oct; 347(1):225-34. PubMed ID: 23902940
[TBL] [Abstract][Full Text] [Related]
4. The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.
Zhang D; McGregor M; Decker MW; Quik M
J Pharmacol Exp Ther; 2014 Oct; 351(1):25-32. PubMed ID: 25034405
[TBL] [Abstract][Full Text] [Related]
5. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
[TBL] [Abstract][Full Text] [Related]
6. Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.
Quik M; Mallela A; Chin M; McIntosh JM; Perez XA; Bordia T
Neurobiol Dis; 2013 Feb; 50():30-41. PubMed ID: 23009753
[TBL] [Abstract][Full Text] [Related]
7. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Quik M; Cox H; Parameswaran N; O'Leary K; Langston JW; Di Monte D
Ann Neurol; 2007 Dec; 62(6):588-96. PubMed ID: 17960553
[TBL] [Abstract][Full Text] [Related]
8. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
9. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
[TBL] [Abstract][Full Text] [Related]
10. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D
Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
[TBL] [Abstract][Full Text] [Related]
11. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Huang LZ; Grady SR; Quik M
J Pharmacol Exp Ther; 2011 Sep; 338(3):932-41. PubMed ID: 21665941
[TBL] [Abstract][Full Text] [Related]
12. Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Lieu CA; Deogaonkar M; Bakay RA; Subramanian T
Parkinsonism Relat Disord; 2011 Jan; 17(1):34-9. PubMed ID: 21074478
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
[TBL] [Abstract][Full Text] [Related]
14. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
Bourque M; Grégoire L; Di Paolo T
Behav Brain Res; 2018 Jan; 337():183-185. PubMed ID: 28917506
[TBL] [Abstract][Full Text] [Related]
15. The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
Cox H; Togasaki DM; Chen L; Langston JW; Di Monte DA; Quik M
Exp Neurol; 2007 May; 205(1):101-7. PubMed ID: 17335811
[TBL] [Abstract][Full Text] [Related]
16. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
[TBL] [Abstract][Full Text] [Related]
17. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Schneider JS; Gonczi H; Decamp E
Brain Res; 2003 Nov; 990(1-2):38-44. PubMed ID: 14568327
[TBL] [Abstract][Full Text] [Related]
18. A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys.
Beck G; Maehara S; Chang PL; Papa SM
Mov Disord; 2018 May; 33(5):805-814. PubMed ID: 29508924
[TBL] [Abstract][Full Text] [Related]
19. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
[TBL] [Abstract][Full Text] [Related]
20. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Andringa G; Lubbers L; Drukarch B; Stoof JC; Cools AR
Behav Pharmacol; 1999 Mar; 10(2):175-82. PubMed ID: 10780830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]